After FDA rejection, EU says yes to Sanofi’s Aubagio in kids with MS

Sanofi’s Aubagio has become the first oral therapy approved for first-line use in children and adolescents with multiple sclerosis in the EU, a few days after the same indication was turned down by the FDA in the US.